Drug intelligence / Profile preview

metoprine

Development stage: Preclinical
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral (based On Typical Administration For Similar Agents And Its Chemical Properties)

Overview

Metoprine is a diaminopyrimidine folate antagonist with potential antineoplastic activity. It acts primarily by inhibiting dihydrofolate reductase (DHFR), leading to decreased cellular folate metabolism and inhibition of cell growth. Additionally, metoprine inhibits histamine-N-methyltransferase, resulting in reduced histamine catabolism. Its lipid solubility allows it to cross the blood-brain barrier[9].

Other names: Methodichlorophen5-(3,4-dichlorophenyl)-6-methylpyrimidine-2,4-diamine

Targets

DHFR (Dihydrofolate reductase)HNMT (Histamine N-methyltransferase)

Beyond the preview

Go deeper on metoprine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metoprine.

Explore the full profile